187 related articles for article (PubMed ID: 26765287)
1. A highly immunogenic vaccine against A/H7N9 influenza virus.
Cao W; Liepkalns JS; Hassan AO; Kamal RP; Hofstetter AR; Amoah S; Kim JH; Reber AJ; Stevens J; Katz JM; Gangappa S; York IA; Mittal SK; Sambhara S
Vaccine; 2016 Feb; 34(6):744-9. PubMed ID: 26765287
[TBL] [Abstract][Full Text] [Related]
2. RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.
Cao W; Liepkalns JS; Kamal RP; Reber AJ; Kim JH; Hofstetter AR; Amoah S; Stevens J; Ranjan P; Gangappa S; York IA; Sambhara S
Cell Immunol; 2016; 304-305():55-8. PubMed ID: 27106062
[TBL] [Abstract][Full Text] [Related]
3. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
4. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
Ou H; Yao H; Yao W; Wu N; Wu X; Han C; Cheng L; Chen K; Chen H; Li L
Vaccine; 2016 Apr; 34(20):2362-70. PubMed ID: 27013436
[TBL] [Abstract][Full Text] [Related]
6. Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.
Wang X; Fu W; Yuan S; Yang X; Song Y; Liu L; Chi Y; Cheng T; Xing M; Zhang Y; Zhang C; Yang Y; Zhu C; Zhang X; Xiong S; Xu J; Zhou D
Sci Rep; 2017 May; 7(1):1854. PubMed ID: 28500340
[TBL] [Abstract][Full Text] [Related]
7. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
[TBL] [Abstract][Full Text] [Related]
8. Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.
Wang L; Chang TZ; He Y; Kim JR; Wang S; Mohan T; Berman Z; Tompkins SM; Tripp RA; Compans RW; Champion JA; Wang BZ
Nanomedicine; 2017 Jan; 13(1):253-262. PubMed ID: 27622321
[TBL] [Abstract][Full Text] [Related]
9. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
10. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
[TBL] [Abstract][Full Text] [Related]
11. Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.
Chen TH; Liu YY; Jan JT; Huang MH; Spearman M; Butler M; Wu SC
Antiviral Res; 2017 Oct; 146():213-220. PubMed ID: 28947234
[TBL] [Abstract][Full Text] [Related]
12. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
[TBL] [Abstract][Full Text] [Related]
13. Recombinant influenza H7 hemagglutinin containing CFLLC minidomain in the transmembrane domain showed enhanced cross-protection in mice.
Wang Y; Zhang Y; Wu J; Lin Y; Wu Z; Wei Y; Wei X; Qin J; Xue C; Liu GD; Cao Y
Virus Res; 2017 Oct; 242():16-23. PubMed ID: 28912070
[TBL] [Abstract][Full Text] [Related]
14. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
16. Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice.
Tang LH; Lim JH; Kuah LF; Lau YF
Vaccine; 2014 Sep; 32(42):5375-8. PubMed ID: 25130540
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.
Yan J; Villarreal DO; Racine T; Chu JS; Walters JN; Morrow MP; Khan AS; Sardesai NY; Kim JJ; Kobinger GP; Weiner DB
Vaccine; 2014 May; 32(24):2833-42. PubMed ID: 24631084
[TBL] [Abstract][Full Text] [Related]
18. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection.
Li Z; Gabbard JD; Johnson S; Dlugolenski D; Phan S; Tompkins SM; He B
PLoS One; 2015; 10(3):e0120355. PubMed ID: 25803697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
